KR20250069693A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20250069693A
KR20250069693A KR1020257014703A KR20257014703A KR20250069693A KR 20250069693 A KR20250069693 A KR 20250069693A KR 1020257014703 A KR1020257014703 A KR 1020257014703A KR 20257014703 A KR20257014703 A KR 20257014703A KR 20250069693 A KR20250069693 A KR 20250069693A
Authority
KR
South Korea
Prior art keywords
erdafitinib
treatment
serum phosphate
cancer
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014703A
Other languages
English (en)
Korean (ko)
Inventor
킴 스투익켄스
루의소 후안 호세 페레스
포르레 페터 마리에 제트. 데
안잘리 나라얀 아바드하니
요한 로리오트
아를레네 오. 시프케르-라트케
엘리자베스 오해건 앤
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250069693(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of KR20250069693A publication Critical patent/KR20250069693A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/574—
    • G01N33/57488—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)
KR1020257014703A 2017-02-06 2018-02-02 암 치료 Pending KR20250069693A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
US62/455,211 2017-02-06
EP17209098 2017-12-20
EP17209098.7 2017-12-20
KR1020197024552A KR20190110581A (ko) 2017-02-06 2018-02-02 암 치료
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024552A Division KR20190110581A (ko) 2017-02-06 2018-02-02 암 치료

Publications (1)

Publication Number Publication Date
KR20250069693A true KR20250069693A (ko) 2025-05-19

Family

ID=61094531

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257014703A Pending KR20250069693A (ko) 2017-02-06 2018-02-02 암 치료
KR1020197024552A Ceased KR20190110581A (ko) 2017-02-06 2018-02-02 암 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197024552A Ceased KR20190110581A (ko) 2017-02-06 2018-02-02 암 치료

Country Status (26)

Country Link
US (2) US11077106B2 (https=)
EP (2) EP4286005A3 (https=)
JP (3) JP2020505425A (https=)
KR (2) KR20250069693A (https=)
CN (1) CN110198716A (https=)
AU (2) AU2018216969B2 (https=)
BR (1) BR112019016043A2 (https=)
CA (1) CA3049737A1 (https=)
DK (1) DK3576740T3 (https=)
ES (1) ES2953005T3 (https=)
FI (1) FI3576740T3 (https=)
HR (1) HRP20230697T1 (https=)
HU (1) HUE062453T2 (https=)
IL (1) IL268463A (https=)
JO (1) JOP20190190B1 (https=)
LT (1) LT3576740T (https=)
MX (2) MX2019009304A (https=)
NZ (2) NZ755301A (https=)
PH (1) PH12019501885A1 (https=)
PL (1) PL3576740T3 (https=)
RS (1) RS64778B1 (https=)
SG (2) SG10202105110VA (https=)
SI (1) SI3576740T1 (https=)
SM (1) SMT202300233T1 (https=)
TW (1) TWI874925B (https=)
UA (1) UA126336C2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
EP3923942A1 (en) * 2019-02-12 2021-12-22 Janssen Pharmaceutica NV Cancer treatment
PH12021552342A1 (en) * 2019-03-29 2022-08-22 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
CN115103678A (zh) * 2020-02-12 2022-09-23 詹森药业有限公司 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HUE062453T2 (hu) * 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128411A1 (en) 2015-02-10 2016-08-18 Astex Therapeutics Limited Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, Vol. 33, No. 30, pp. 3401-3408

Also Published As

Publication number Publication date
DK3576740T3 (da) 2023-07-24
TW202402290A (zh) 2024-01-16
JP2025024064A (ja) 2025-02-19
AU2024201871B2 (en) 2026-02-26
US20200022976A1 (en) 2020-01-23
NZ755301A (en) 2025-12-19
HRP20230697T1 (hr) 2023-10-13
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
ES2953005T3 (es) 2023-11-07
LT3576740T (lt) 2023-08-10
IL268463A (en) 2019-09-26
EP4286005A3 (en) 2024-03-06
EP4286005A2 (en) 2023-12-06
MX2019009304A (es) 2019-09-19
JP7668777B2 (ja) 2025-04-25
SMT202300233T1 (it) 2023-09-06
US11077106B2 (en) 2021-08-03
TWI874925B (zh) 2025-03-01
US20220110935A1 (en) 2022-04-14
UA126336C2 (uk) 2022-09-21
CA3049737A1 (en) 2018-08-09
MX2022007955A (es) 2022-07-27
CN110198716A (zh) 2019-09-03
AU2018216969A1 (en) 2019-07-25
HUE062453T2 (hu) 2023-11-28
JOP20190190A1 (ar) 2019-08-04
KR20190110581A (ko) 2019-09-30
JP2020505425A (ja) 2020-02-20
BR112019016043A2 (pt) 2020-03-31
SG10202105110VA (en) 2021-06-29
RS64778B1 (sr) 2023-11-30
EP3576740B1 (en) 2023-06-14
EP3576740A1 (en) 2019-12-11
PL3576740T3 (pl) 2023-09-11
PH12019501885A1 (en) 2020-06-29
FI3576740T3 (fi) 2023-08-31
JOP20190190B1 (ar) 2024-04-18
NZ796822A (en) 2025-12-19
AU2018216969B2 (en) 2024-04-11
AU2024201871A1 (en) 2024-04-11
SI3576740T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
JP2026016402A (ja) 癌治療
HK40103983A (en) Cancer treatment
EP3946341A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052711B1 (ru) Лечение рака
HK40013982A (en) Cancer treatment
HK40018978A (en) Cancer treatment
HK40018978B (en) Cancer treatment
EA051616B1 (ru) Лечение рака

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000